Elanco
ELANELAN · Stock Price
Historical price data
Overview
Elanco is a publicly traded, global animal health leader with a $11.73B market cap, spun off from Eli Lilly in 2018. The company's mission, 'making life better for animals, makes life better,' is executed through a dual-pillar strategy focusing on high-growth companion animal health and productivity-enhancing farm animal solutions. Its achievements include a robust portfolio of market-leading brands like Credelio and Seresto, a global commercial footprint, and a commitment to a consistent flow of innovation. Elanco's strategy leverages its integrated technology platforms and digital transformation initiatives to drive sustainable growth and address global challenges like food security and the human-animal bond.
Technology Platform
A diversified platform integrating small molecule chemistry, biologics & vaccines, medicated feed additives, and digital health solutions to address animal health holistically.
Pipeline
14| Drug | Indication | Stage | Watch |
|---|---|---|---|
| zonisamide | Bipolar Disorders | Approved | |
| cefepime + ceftriaxone | Pneumonia | Approved | |
| tizanidine hydrochloride capsule | Multiple Sclerosis | Phase 3 | |
| Prialt (ziconotide) | Pain | Phase 3 | |
| Ziconotide | Pain | Phase 3 |